Controversies in the management of ovarian cancer

International Journal of Gynecological Cancer

Volumn 7, Issue SUPPL. 1, 1997, Pages 27-32

  Ozols, R F ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Cisplatin cyclophosphamide; Cytoreductive surgery; Dose intensity; Intraperitoneal chemotherapy; New standard chemotherapy; Paclitaxel cisplatin; Whole abdomen irradiation

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN;

ADVANCED CANCER; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0030795163     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.7.s1.4.x     Document Type: Conference Paper

References (29)

1. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 1992; 47: 159-66.
2. Hunter RW, Alexander NDE, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992; 166: 504-11.
3. Van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecologic Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995: 332: 629-34.
4. Schwartz PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 1994; 53: 33-7.
5. Freidman JB, Weiss NS. Sounding board. Second thoughts about second-look laparotomy in advanced ovarian cancer. N Engl J Med 1990; 322: 1079-80.
6. Omura GA, Buyse M, Marsoni S, et al. CP versus CAP chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991; 9: 1668-74.
7. A'Hem RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726-32.
8. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
9. Bookman MA, McGuire WPIII, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14: 1895-906.
10. Vermorken JB, ten Bokkel Huinink WW, Eisenhauer E, et al. Carboplatin versus cisplatin. Ann Oncol 1993; 4: 41-8.
11. van der Velden J, Gitsch G, Wain GV, et al. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995; 5: 301-4.
12. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13: 1589-99.
13. Conte PF, Bruzzone M, Carino F, et al. High dose versus low dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996; 14: 351-6.
14. Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996; 14: 2113-19.
15. Jakobsen A. Dose intensity study of carboplatin in ovarian cancer. Proc Int Gynecol Cancer Soc 1995; 5: 11 (abstract 36).
16. Gore ME, Mainwaring PN, Macfarlane V, et al. A randomised study of high versus standard dose carboplatin in patients (pts) with advanced epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 1996; 15: 284 (Abstract 769).
17. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-14.
18. Kohn EC, Sarosy G, Bicher A, et al. Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24.
19. Omura GA, Brady MF, Delmore JE, et al. A randomized trial of paclitaxel (t) at 2 dose levels and filgrastim (g; G-CSF) at 2 doses in platinum (p) pretreated epithelial ovarian cancer (ovca): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. Proc Am Soc Clin Oncol 1996; 15: 280 (Abstract 755).
20. Thigpen T. High-dose chemotherapy with autologous bone marrow support in ovarian carcinoma: the bottom line, more or less. Gynecol Oncol 1995; 57: 275-7.
21. Fennelly D, Schneider J, Spriggs D, et al. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 1995; 13: 1160-6.
22. Markman M. Intraperitoneal chemotherapy. In: Markman M, Hoskins WJ, eds. Cancer of the Ovary. New York, NY: Raven Press, 1993: 317-26.
23. Alberts DS, Liu PY, Hannigan EV, et al. Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) vs IV CDDP/IV CPA in patients (PTS) with optimal disease stage III ovarian cancer: A SWOG-GOG-ECOG intergroup study. (INT 0051). Proc Am Soc Clin Oncol 1995; 14: 273 (Abstract 760).
24. Dembo AJ, Bush RS, Beale FA, et al. The Princess Margaret Hospital study of ovarian cancer: stages I, II, and asymptomatic III presentations. Cancer Treat Rep 1979; 63: 249-54.
25. Mychalczak BR, Fuks Z. The current role of radiotherapy in the management of ovarian cancer. Hematol Oncol Clin North Am 1992; 16: 895-914.
26. Sorbe B, Tropé C, Nordal R, et al. Chemotherapy versus radiotherapy as consolidation treatment of ovarian carcinoma stage III at surgical complete remission from induction chemotherapy. Proc Am Soc Clin Oncol 1996; 15: 287 (Abstract 780).
27. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. Cancer 1991; 68: 269-71.
28. Edwards RP, Lembersky BC, Kunschner AJ. Intraperitoneal interleukin-2 (IL-2) produces durable responses for refractory ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 333 (Abstract).
29. Pujade-Lauraine E, Guastalla J-P, Colombo N, et al. Intraperitoneal recombinant Interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996; 14: 343-50.